The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISHL HL Update 2021 | NIVAHL: nivolumab and AVD in early-stage unfavorable HL
Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, outlines results of the NIVAHL trial (NCT03004833), a prospective, randomized Phase II study evaluating nivolumab and doxorubicin, vinblastine, and dacarbazine (AVD) in patients with early-stage unfavorable classical Hodgkin lymphoma (HL). Nivolumab-based first-line treatment led to high remission rates and excellent 12-month progression-free survival and warrants further evaluation in this patient population. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.
